Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients
Ramon Staeger, Aizhan Tastanova, Adhideb Ghosh, Nicola Winkelbeiner, Prachi Shukla, Isabel Kolm, Patrick Turko, Adel Benlahrech, Jane Harper, Anna Broomfield, Antonio Camera, Marianna Ambrosio, Veronika Haunerdinger, Phil F. Cheng, Egle Ramelyte, James Pham, Stefanie Kreutmair, Burkhard Becher, Mitchell P. Levesque, Reinhard Dummer, Barbara Meier-Schiesser
Ramon Staeger, Aizhan Tastanova, Adhideb Ghosh, Nicola Winkelbeiner, Prachi Shukla, Isabel Kolm, Patrick Turko, Adel Benlahrech, Jane Harper, Anna Broomfield, Antonio Camera, Marianna Ambrosio, Veronika Haunerdinger, Phil F. Cheng, Egle Ramelyte, James Pham, Stefanie Kreutmair, Burkhard Becher, Mitchell P. Levesque, Reinhard Dummer, Barbara Meier-Schiesser
View: Text | PDF
Clinical Research and Public Health Dermatology Oncology

Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients

Abstract

BACKGROUND Tebentafusp is the first T cell receptor–based bispecific protein approved for clinical use in HLA-A*02:01+ adult patients with unresectable/metastatic uveal melanoma. It redirects T cells toward gp100-expressing target cells, frequently inducing skin-related early adverse events.METHODS This study investigated immunological and cellular responses using single-cell and spatial analysis of skin biopsies from patients with metastatic uveal melanoma treated with tebentafusp.RESULTS 81.8% of patients developed acute cutaneous adverse events, which correlated with improved survival. Multimodal analysis revealed a brisk infiltration of CD4+ and CD8+ T cells, while melanocyte numbers declined. Single-cell RNA-sequencing revealed T cell activation, proliferation, and IFN-γ/cytotoxic gene upregulation. CD8+ T cells colocalized with melanocytes and upregulated LAG3, suggesting potential for combination therapies with tebentafusp. Melanocytes upregulated antigen presentation and apoptotic pathways, while pigmentation gene expression decreased. However, gp100 remained stably expressed.CONCLUSION Sequential skin biopsies enable in vivo pharmacodynamic modeling of tebentafusp, offering insights into immune activation, toxicity, and treatment response. Examining the on-target effects of bispecifics in tissues amenable to longitudinal sampling enhances our understanding of toxicity and therapeutic escape mechanisms, guiding strategies for treatment optimization.FUNDING Cancer Research Foundation, Swiss National Science Foundation (323630_207029, 733 310030_170320, 310030_188450, CRSII5_183478), Iten-Kohaut Foundation, European Research Council no. 882424, University Priority Project Translational Cancer Research of the University of Zurich (UZH), UZH PostDoc grant (K-85810-02-01).

Authors

Ramon Staeger, Aizhan Tastanova, Adhideb Ghosh, Nicola Winkelbeiner, Prachi Shukla, Isabel Kolm, Patrick Turko, Adel Benlahrech, Jane Harper, Anna Broomfield, Antonio Camera, Marianna Ambrosio, Veronika Haunerdinger, Phil F. Cheng, Egle Ramelyte, James Pham, Stefanie Kreutmair, Burkhard Becher, Mitchell P. Levesque, Reinhard Dummer, Barbara Meier-Schiesser

×

Figure 2

Spatial analysis of cutaneous inflammatory infiltrate on tebentafusp.

Options: View larger image (or click on image) Download as PowerPoint
Spatial analysis of cutaneous inflammatory infiltrate on tebentafusp. (A...
(A) Representative mIHC scans of baseline, acAE, and VLPD skin samples. (B) Heatmap with scaled marker expression. (C) Cell-type composition at baseline (n = 9), acAE (n = 9), and VLPD (n = 5). Boxplots show the centered log ratio–transformed cell numbers (t test). (D) Epidermal cell sizes at baseline and acAE (n = 3, paired; Cohen’s d = 0.30). (E) Epidermal cell death at baseline and acAE skin samples, shown by TUNEL-positive and -negative epidermal nuclei (n = 5, paired). (F) Representative plot of the spatial distribution of macrophages, CD4+, and CD8+ T cells, relative to epidermis (gray) at baseline, acAE, and VLPD. (G) Spatial density of immune cells relative to melanocytes at baseline (n = 9), acAE (n = 9), and VLPD (n = 5), ranging from 0 μm (most proximal) to 100 μm (most distant) in 10 μm steps. *P < 0.05; ***P < 0.001; ****P < 0.0001.